Presentations & Posters

  • 1) Pharmacokinetics and efficacy of ectolysin P128 in a mouse model of systemic Methicillin Resistant Staphylococcus aureus (MRSA) infection.
    Presented at ASM Microbe 2017, June 2017
  • 2) Preclinical studies of anti-staphylococcal ectolysin P128 for potential systemic hypersensitivity and evaluation of efficacy in Staphylococcus aureus bacteremia with renal abscesses in rats.
    Presented at ASM Microbe 2017, June 2017
  • 3) Reversal of drug resistant phenotype of Staphylococcus clinical strains by synergistic action of P128 and antibiotics.
    Presented at ASM Microbe 2017, June 2017
  • 4) Bactericidal Activity of P128 on Coagulase Negative Staphylococci: Alone and in Combination with Antibiotics.
    Presented at 27th ECCMID, April 2017
  • 5) Killing of Persisters,Stationary Phase or Starved Cells of MRSA and CoNS by Anti-Staphylococcal Protein P128 .
    Presented at 27th ECCMID, April 2017
  • 6) In Vivo Synergy and Efficacy of P128 in Combination with Standard of Care Antibiotics in Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia
    Presented at 27th ECCMID, April 2017
  • 7) Eradication of Coagulase Negative Staphylococcus Biofilms by P128 Alone and Synergistic Inhibition in Combination with Antibiotics
    Oral presentation. Presented at 27th ECCMID, April 2017
  • 8) P128, a Novel Anti-Staphylococcal Protein to Treat S. aureus Infections in Wounds and in Bacteremia.
    Presented at New Antibacterial Discovery & Development- Gordon Research conference, March 2016
  • 9) Mechanism of Action of Anti-Staphylococcal Protein P128.
    Presented at ICAAC, September 2013
  • 10) Preclinical studies on P128, a novel anti-Staphylococcal protein.
    Presented at the ASM 2010 Conference, May 2010
  • 11) Preclinical Development of a novel antistaphylococcal Protein (P128) for Clearance of Nasal MRSA and for Prevention of MRSA colonization.
    Presented at Gordon Research Conference on Staphylococcal Diseases, September 2009